A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT ID: NCT02763319
Last Updated: 2025-07-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
453 participants
INTERVENTIONAL
2016-11-28
2024-06-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
NCT05551936
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
NCT02594163
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
NCT01491841
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00831597
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
NCT04433182
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tafasitamab and bendamustine
Tafasitamab and bendamustine
Tafasitamab
Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
Bendamustine (BEN)
Rituximab and bendamustine
Rituximab and bendamustine
Rituximab (RTX)
Rituximab: Dose: 375 mg/m2 IV
Bendamustine (BEN)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab (RTX)
Rituximab: Dose: 375 mg/m2 IV
Tafasitamab
Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
Bendamustine (BEN)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed diagnosis, according to the World Health Organization (WHO, 2008) classification, of: DLBCL NOS, THRLBCL, EBV-positive DLBCL, composite lymphoma with a DLBCL component with a DLBCL relapse subsequent to DLBCL treatment, disease transformed from an earlier diagnosis of low grade lymphoma (i.e. an indolent pathology such as follicular lymphoma, marginal zone lymphoma) into DLBCL with a DLBCL relapse subsequent to DLBCL treatment.
3. Fresh tumour tissue for central pathology review must be provided as an adjunct to participation in this study. Should it not be possible to obtain a fresh tumour tissue sample, archival paraffin embedded tumour tissue acquired ≤3 years prior to screening for this protocol must be available for this purpose.
4. Patients must have:
1. relapsed or refractory DLBCL
2. at least one bidimensionally measurable disease site. The lesion must have a greatest transverse diameter of ≥1.5 cm and greatest perpendicular diameter of ≥1.0 cm at baseline. The lesion must be positive on PET scan
3. received at least one, but no more than three previous systemic therapy lines for the treatment of DLBCL. At least one previous therapy line must have included a CD20-targeted.
4. ECOG 0 to 2
5. Patients after failure of ASCT or patients considered in the opinion of the investigator currently not eligible for HDC with subsequent ASCT.
6. Patients must meet the following laboratory criteria at Screening:
1. ANC ≥1.5 × 109/L (unless secondary to bone marrow involvement by DLBCL)
2. PLTs ≥90 × 109/L (unless secondary to bone marrow involvement by DLBCL) and absence of active bleeding
3. total serum bilirubin ≤2.5 × ULN unless secondary to Gilbert's syndrome (or pattern consistent with Gilbert's) or documented liver involvement by lymphoma. Patients with Gilbert's syndrome or documented liver involvement by lymphoma may be included if their total bilirubin is ≤5 x ULN
4. ALT, AST and AP ≤3 × ULN or \<5 × ULN in cases of documented liver involvement by lymphoma
5. serum creatinine ≤2.0 x ULN or creatinine clearance must be ≥40 mL/min calculated using a standard Cockcroft-Gault formula (Cockroft \& Gault, 1976)
7. For a female of childbearing potential (FCBP), a negative pregnancy test must be confirmed before enrolment. An FCBP must commit to take highly effective contraceptive precautions without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. An FCBP must refrain from breastfeeding and donating blood or oocytes during the course of the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later. Restrictions concerning blood donations apply as well to females who are not of childbearing potential.
8. Males must use an effective barrier method of contraception without interruption during the study and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later, if the patient is sexually active with an FCBP. Males must refrain from donating blood or sperm during study participation and for 3, 6 or 12 months after the last dose of Tafasitamab, BEN or RTX respectively, whichever is later.
9. In the opinion of the investigator, the patients must:
1. be able to comply with all study-related procedures, medication use, and evaluations
2. be able to understand and give informed consent
3. not be considered to be potentially unreliable and/or not cooperative.
Exclusion Criteria
2. Patients who had a major surgery less than 30 days prior to Day 1 dosing
3. Patients who have, within 14 days prior to Day 1 dosing:
1. not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy
2. received live vaccines
3. required parenteral antimicrobial therapy for active, intercurrent systemic infections
4. Patients who:
1. in the opinion of the investigator, have not recovered sufficiently from the adverse toxic effects of prior therapies, major surgeries or significant traumatic injuries
2. were previously treated with CD19-targeted therapy or BEN
3. have a history of previous severe allergic reactions to compounds of similar biological or chemical composition to Tafasitamab, RTX, murine proteins or BEN, or the excipients contained in the study drug formulations
4. have undergone ASCT within a period of ≤3 months prior to signing the informed consent form. Patients who have a more distant history of ASCT must exhibit full haematological recovery before enrolment into the study.
5. have undergone previous allogeneic stem cell transplantation
6. concurrently use other anticancer or experimental treatments
5. Prior history of malignancies other than DLBCL, unless the patient has been free of the disease for ≥3 years prior to Screening. Exceptions to the ≥3-year time limit include history of the following:
1. basal cell carcinoma of the skin
2. squamous cell carcinoma of the skin
3. carcinoma in situ of the cervix, breast and bladder
f) incidental histological finding of prostate cancer (Tumour/Node/Metastasis \[TNM\] stage of T1a or T1b)
6. Patients with:
1. positive hepatitis B and/or C serology
2. known seropositivity for or history of active viral infection with HIV
3. evidence of active, severe uncontrolled systemic infections or sepsis
4. a history or evidence of severely immunocompromised state
5. a history or evidence of severe hepatic impairment (total serum bilirubin \> 3 mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma
6. a history or evidence of clinically significant cardiovascular, cerebrovascular, CNS and/or other disease that, in the investigator's opinion, would preclude participation in the study or compromise the patient's ability to give informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Incyte Medical Director
Role: STUDY_DIRECTOR
Incyte Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MorphoSys Research Site
Anaheim, California, United States
MorphoSys Research Site
Bakersfield, California, United States
Morphosys Research Site
Burbank, California, United States
Morphosys Research Site
Fresno, California, United States
MorphoSys Research Site
Los Angeles, California, United States
MorphoSys Research Site
Whittier, California, United States
MorphoSys Research Site
Plainville, Connecticut, United States
MorphoSys Research Site
Skokie, Illinois, United States
MorphoSys Research Site
Detroit, Michigan, United States
MorphoSys Research Site
Rochester, Minnesota, United States
MorphoSys Research Site
Hattiesburg, Mississippi, United States
Morphosys Research site
Jackson, Mississippi, United States
Morphosys Research Site
Morristown, New Jersey, United States
MorphoSys Research Site
New York, New York, United States
MorphoSys Research Site
Stony Brook, New York, United States
MorphoSys Research Site
Oklahoma City, Oklahoma, United States
MorphoSys Research Site
Knoxville, Tennessee, United States
Morphosys Research Site
Lubbock, Texas, United States
MorphoSys Research Site
Adelaide, , Australia
MorphoSys Research Site
Albury, , Australia
MorphoSys Research Site
Bedford Park, , Australia
MorphoSys Research Site
Box Hill, , Australia
MorphoSys Research Site
Concord, , Australia
MorphoSys Research Site
Frankston, , Australia
MorphoSys Research SIte
Garran, , Australia
MorphoSys Research Site
Geelong, , Australia
MorphoSys Research Site
Gosford, , Australia
MorphoSys Research Site
Nedlands, , Australia
MorphoSys Research Site
South Brisbane, , Australia
MorphoSys Research Site
St Albans, , Australia
MorphoSys Research Site
Innsbruck, , Austria
Morphosys Research Site
Edmonton, Alberta, Canada
MorphoSys Research Site
Winnipeg, Manitoba, Canada
MorphoSys Research Site
Saint John, New Brunswick, Canada
Morphosys Research Site
St. John's, Newfoundland and Labrador, Canada
MorphoSys Research Site
Kingston, Ontario, Canada
MorphoSys Research Site
Greenfield Park, Quebec, Canada
Morphosys Research Site
Montreal, Quebec, Canada
MorphoSys Research Site
Saskatoon, , Canada
MorphoSys Research Site
Zagreb, , Croatia
MorphoSys Research Site
Hradec Králové, , Czechia
Morphosys Research site
Olomouc, , Czechia
Morphosys Research Site
Prague, , Czechia
MorphoSys Research Site
Prague, , Czechia
MorphoSys Research Site
Oulu, , Finland
MorphoSys Research Site
Tampere, , Finland
MorphoSys Research Site
Grenoble, , France
MorphoSys Research Site
Le Mans, , France
MorphoSys Research Site
Aachen, , Germany
MorphoSys Research Site
Berlin, , Germany
MorphoSys Research Site
Berlin, , Germany
MorphoSys Research Site
Düsseldorf, , Germany
MorphoSys Research Site
Giessen, , Germany
Morphosys Research Site
Homburg, , Germany
MorphoSys Research Site
Leipzig, , Germany
MorphoSys Research Site
Mainz, , Germany
MorphoSys Research Site
Munich, , Germany
MorphoSys Research Site
Munich, , Germany
MorphoSys Research Site
Mutlangen, , Germany
Morphosys Research Site
Münster, , Germany
MorphoSys Research Site
Rostock, , Germany
MorphoSys Research Site
Stuttgart, , Germany
MorphoSys Research Site
Stuttgart, , Germany
MorphoSys
Traunstein, , Germany
MorphoSys
Budapest, , Hungary
MorphoSys Research Site
Debrecen, , Hungary
MorphoSys Research Site
Győr, , Hungary
MorphoSys
Szeged, , Hungary
MorphoSys Research Site
Haifa, , Israel
MorphoSys Research Site
Jerusalem, , Israel
MorphoSys Research Site
Jerusalem, , Israel
MorphoSys Research Site
Kfar Saba, , Israel
MorphoSys Research Site
Tel Aviv, , Israel
MorphoSys Research Site
Alessandria, , Italy
MorphoSys Research Site
Bologna, , Italy
MorphoSys Research Site
Campobasso, , Italy
MorphoSys Research Site
Cona, , Italy
MorphoSys Research Site
Genova, , Italy
MorphoSys Research Site
Lecce, , Italy
MorphoSys Research Site
Meldola, , Italy
MorphoSys Research Site
Monza, , Italy
MorphoSys Research Site
Napoli, , Italy
Morphosys Research Site
Novara, , Italy
MorphoSys Research Site
Orbassano, , Italy
MorphoSys Research Site
Parma, , Italy
MorphoSys Research Site
Pavia, , Italy
MorphoSys Research Site
Pisa, , Italy
MorphoSys Research Site
Ravenna, , Italy
MorphoSys Research Site
Reggio Emilia, , Italy
MorphoSys Research Site
Rimini, , Italy
MorphoSys Research Site
Rome, , Italy
MorphoSys Research Site
Rome, , Italy
Morphosys Research Site
Terni, , Italy
MorphoSys Research Site
Turin, , Italy
Morphosys Research Site
Turin, , Italy
MorphoSys Research Site
Addington, , New Zealand
MorphoSys Research Site
Auckland, , New Zealand
MorphoSys Research Site
Grafton, , New Zealand
Morphosys Research Site
Bydgoszcz, , Poland
MorphoSys Research Site
Gdynia, , Poland
MorphoSys Research Site
Krakow, , Poland
MorphoSys Research Site
Legnica, , Poland
MorphoSys Research Site
Lodz, , Poland
MorphoSys Research Site
Lublin, , Poland
Morphosys Research Site
Warsaw, , Poland
MorphoSys Research Site
Wroclaw, , Poland
MorphoSys Research Site
Braga, , Portugal
MorphoSys Research Site
Coimbra, , Portugal
MorphoSys Research Site
Coimbra, , Portugal
MorphoSys Research Site
Matosinhos Municipality, , Portugal
MorphoSys Research Site
Porto, , Portugal
MorphoSys Research Site
Porto, , Portugal
MorphoSys Research Site
Pragal, , Portugal
MorphoSys Research Site
Bucharest, , Romania
MorphoSys Research Site
Bucharest, , Romania
MorphoSys Research Site
Iași, , Romania
MorphoSys Research Site
Belgrade, , Serbia
MorphoSys Research Site
Kragujevac, , Serbia
MorphoSys Research Site
Singapore, , Singapore
MorphoSys Research Site
Singapore, , Singapore
MorphoSys Research Site
Singapore, , Singapore
MorphoSys Research Site
Singapore, , Singapore
MorphoSys Research Site
Busan, , South Korea
MorphoSys Research Site
Goyang-si, , South Korea
MorphoSys Research Site
Incheon, , South Korea
MorphoSys Research Site
Jeonju, , South Korea
MorphoSys Research Site
Seongnam, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Seoul, , South Korea
MorphoSys Research Site
Ulsan, , South Korea
MorphoSys Research Site
Cadiz, , Spain
MorphoSys Research Site
Girona, , Spain
MorphoSys Research Site
L'Hospitalet de Llobregat, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Madrid, , Spain
MorphoSys Research Site
Palma de Mallorca, , Spain
MorphoSys Research Site
Pamplona, , Spain
MorphoSys Research Site
Pozuelo de Alarcón, , Spain
MorphoSys
Sabadell, , Spain
MorphoSys Research Site
Salamanca, , Spain
MorphoSys Research Site
Valencia, , Spain
Morphosys Research Site
Chang-hua, , Taiwan
Morphosys Research Site
Hualien City, , Taiwan
Morphosys Research Site
Taichung, , Taiwan
MorphoSys Research Site
Adana, , Turkey (Türkiye)
MorphoSys Research Site
Ankara, , Turkey (Türkiye)
MorphoSys Research Site
Ankara, , Turkey (Türkiye)
MorphoSys Research Site
Bornova, , Turkey (Türkiye)
MorphoSys Research Site
Gaziantep, , Turkey (Türkiye)
MorphoSys Research Site
Izmir, , Turkey (Türkiye)
MorphoSys Research Site
Manisa, , Turkey (Türkiye)
MorphoSys Research Site
Samsun, , Turkey (Türkiye)
Morphosys Research Site
Birmingham, , United Kingdom
MorphoSys Research Site
Leeds, , United Kingdom
MorphoSys Research Site
Southend-on-Sea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-004689-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MOR208C204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.